Alnylam’s strategy to head off CRISPR threat
Market access, right indications key to Alnylam holding its ground
Market access and the right indications are key to Alnylam holding its ground.
The disruptive potential CRISPR demonstrated last weekend led Alnylam to shed over $1 billion in market cap Monday, but the RNAi pioneer has been readying for this moment, building a pipeline strategy to counter the prospect it will end up playing second fiddle to the newer technology.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) has been anticipating the threat, CEO John Maraganore told BioCentury. It believes its long-term pipeline and commercialization game plan will enable it to maintain relevance when in vivo CRISPR meets the market.
“We are always thinking about the emerging technologies we should be aware of that may make a given target more or less interesting for us to pursue,” Maraganore said.
The company has been constructing a pipeline around indications where RNAi has potential benefits, said Maraganore, including those where permanent gene knockdown isn’t